Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018

Immune checkpoint inhibitors (CPIs) have radically changed outcomes for patients diagnosed with metastatic melanoma globally in the last 10 years, based on evidence of overall survival (OS) benefits generated from international randomised controlled trials (RCTs). Since RCTs do not always reflect re...

Descripción completa

Detalles Bibliográficos
Autores principales: Board, Ruth, Smittenaar, Rebecca, Lawton, Sarah, Liu, Hanhua, Juwa, Bukky, Chao, David, Corrie, Pippa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Cancer Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821238/
https://www.ncbi.nlm.nih.gov/pubmed/32838478
http://dx.doi.org/10.1002/ijc.33266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821238/
https://www.ncbi.nlm.nih.gov/pubmed/32838478
http://dx.doi.org/10.1002/ijc.33266

Ejemplares similares